Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 6473 - 6480 of 12032 results
Memo to Massachusetts Employers for 2018 and 2019: How Not to Comply with the EMAC New Rules
December 13, 2017| Blog| Viewpoint
Insurance Commissioners Approve Data Security Model Law
December 12, 2017| Blog| Viewpoint
Proposed Law Would Criminalize Failures to Report Data Breaches
December 12, 2017| Blog| Viewpoint
SAS v. Matal – Overview of Oral Arguments in the Supreme Court
December 12, 2017| Blog| Viewpoint
GOP under pressure on bond issue in tax bill
December 12, 2017| News
Is the Defense Bar Losing the "Securities Class Action War?"
December 11, 2017| Blog| Viewpoint
Two Data Breach Bills Introduced in US Senate
December 11, 2017| Blog| Viewpoint
ML Strategies Health Care Preview - Week of December 11th
December 11, 2017| Blog| Viewpoint
News & Press Releases
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|